FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sikri Vishal		 2. Issuer Name and Ticker or Trading Symbol

NEOGENOMICS INC [ NEO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President Advanced Diagnostics
(Last)          (First)          (Middle)

9490 NEOGENOMICS WAY		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/1/2023
(Street)

FORT MYERS, FL 33912		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 6/1/2023  F  21406 (1)D$0 127716 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $8.42            (2)(3)6/1/2029 Common Stock 319112  319112 D  
Stock Option (Right to Buy) $19.65            (4)5/11/2030 Common Stock 39683  39683 D  
Restricted Stock Unit $0            (5) (6)Common Stock 21204  21204 D  
Performance Stock Unit $0           5/11/2026 (7) (6)Common Stock 21204  21204 D  
Explanation of Responses:
(1) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the June 1, 2023 vesting of restricted stock.
(2) On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.
(3) On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.
(4) On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date.
(5) On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
(6) Once vested, the shares of common stock are not subject to expiration.
(7) On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Sikri Vishal
9490 NEOGENOMICS WAY
FORT MYERS, FL 33912

President Advanced Diagnostics
Signatures
/s/ Ali Olivo, Attorney-in-Fact6/2/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NeoGenomics (NASDAQ:NEO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse NeoGenomics
NeoGenomics (NASDAQ:NEO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse NeoGenomics